Generic Name and Formulations:
Fluticasone propionate 50mcg/spray; aqueous nasal spray.
Various generic manufacturers
Indications for Fluticasone:
Perennial nonallergic rhinitis.
Initially 2 sprays in each nostril once daily or 1 spray in each nostril twice daily (AM and PM). Maintenance: may reduce to 1 spray in each nostril daily. Max total daily doses: 2 sprays in each nostril (200mcg/day).
<4yrs: not established. ≥4yrs: initially 1 spray in each nostril once daily; may increase to 2 sprays in each nostril once daily. Maintenance: 1 spray in each nostril once daily. Max total daily doses: 2 sprays in each nostril (200mcg/day).
Maintain regular regimen. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, depression). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and candida infection or other nasal mucosal changes. Avoid eyes. Pregnancy (Cat.C). Nursing mothers.
Avoid ritonavir. Caution with potent CYP3A4 inhibitors (eg, ketoconazole).
Headache, pharyngitis, epistaxis, nasal burning, asthma symptoms, GI upset, cough, reduced growth velocity in children.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|